Recommended Dosage for Haloperidol and Promethazine in Rapid Tranquilisation
For rapid tranquilisation of an acutely agitated adult, administer haloperidol 5 mg intramuscularly combined with promethazine 25-50 mg intramuscularly. This combination is supported by guideline-level evidence and demonstrates superior efficacy to monotherapy in achieving rapid sedation 1.
Specific Dosing Protocol
Standard Adult Dose
- Haloperidol: 5 mg IM (FDA-approved range: 2-5 mg IM for acute agitation) 2
- Promethazine: 25-50 mg IM 1, 3
The combination produces more patients tranquil or asleep at 15,30,60, and 120 minutes compared to lorazepam monotherapy, with 96% of patients achieving tranquility or sleep by 4 hours 1.
Alternative Lower-Dose Approach
Recent evidence suggests haloperidol 2.5 mg + promethazine 25 mg may be effective with potentially fewer adverse effects 4. However, this lower dose showed inferior agitation reduction compared to other combinations in head-to-head trials and carries a higher risk of extrapyramidal symptoms, making it a second-line option 4.
Geriatric Dosing Considerations
For patients ≥65 years, use haloperidol ≤0.5 mg initially 5. The 2025 geriatric emergency guidelines demonstrate that low-dose haloperidol (≤0.5 mg) achieves similar efficacy to higher doses in older adults while reducing adverse events 6, 5. Promethazine dosing should similarly be reduced to 12.5-25 mg in this population 3.
Administration Guidelines
Route and Technique
- Deep intramuscular injection is the preferred route for promethazine 3
- Haloperidol can be administered IM at 2-5 mg doses 2
- Never administer promethazine intra-arterially due to risk of severe arteriospasm and gangrene 3
- Subcutaneous injection of promethazine is contraindicated 3
Redosing Protocol
- Subsequent doses may be given as often as every hour if needed, though 4-8 hour intervals are typically satisfactory 2
- Monitor for clinical response at 15-20 minute intervals 1
- If inadequate response at 20 minutes, consider repeat dosing rather than switching agents
Critical Safety Considerations
Extrapyramidal Symptoms Risk
The haloperidol-promethazine combination carries a higher risk of extrapyramidal symptoms within 24 hours compared to haloperidol-midazolam or second-generation antipsychotics 4. Have diphenhydramine or benztropine readily available for dystonic reactions.
Respiratory Depression
Avoid this combination in patients with compromised respiratory function. The 2025 geriatric guidelines found serious adverse events occurred in 16.8% of older adults receiving antipsychotic or anxiolytic medications, with respiratory depression being a primary concern 6.
QTc Prolongation
Both haloperidol and promethazine can prolong QTc interval. While the combination has been extensively studied without significant cardiac events reported 1, baseline ECG screening is prudent in patients with cardiac risk factors.
Comparative Context
The haloperidol-promethazine combination represents a Level C recommendation from emergency medicine guidelines 1. While effective, newer evidence suggests:
- Droperidol monotherapy (if available) provides faster sedation than haloperidol 1
- Midazolam achieves more rapid sedation (18.3 min vs 28.3 min for haloperidol) but poses elevated risk in older adults 1, 6
- Second-generation antipsychotics (olanzapine 10 mg IM, ziprasidone 20 mg IM) show similar efficacy with lower extrapyramidal symptom rates 4, 7
Clinical Algorithm
- Assess patient age: If ≥65 years → use haloperidol ≤0.5 mg + promethazine 12.5-25 mg
- Standard adult (<65 years): haloperidol 5 mg + promethazine 25-50 mg IM
- Evaluate at 20 minutes: If inadequate response, may repeat dosing
- Monitor for adverse effects: Particularly dystonia, respiratory depression, and over-sedation
- Transition to oral therapy within 12-24 hours once patient stabilized 2
The evidence consistently supports this combination as effective for rapid tranquilisation, though clinicians should weigh the increased extrapyramidal symptom risk against the need for rapid control 1, 4.